Key Takeaways
- NextFerm Technologies Ltd. is suspending operations after a significant drop in share price and impending financial challenges.
- The company is focused on selling its assets to mitigate roughly $1.45 million in commitments, with only $230,000 in cash available.
- Founded by former Enzymotec employees, NextFerm specialized in yeast-based food ingredients but has struggled to achieve profitability and secure additional funding.
Business Suspension and Financial Struggles
NextFerm Technologies Ltd., an Israeli food-tech company, has announced the suspension of its operations, marking the end of its independent business journey. The decision follows a 50% plunge in its stock price after announcing its plans to cease business activity, aside from a joint venture in India. The company’s market capitalization has shrunk to NIS 7 million, representing a staggering 99.5% decline since its initial public offering (IPO) in January 2021.
In its notification to the Tel Aviv Stock Exchange (TASE), NextFerm stated that its board of directors informed 11 employees about the operational suspension. Management is now tasked with liquidating company assets and technologies to minimize commitments while attempting to maintain its status as a “going concern.” The board has also instructed management to search for a buyer, either for the company or its assets, as they navigate this challenging phase.
NextFerm’s cash reserves are perilously low, with only $230,000 on hand against obligations totaling $1.45 million, including $1.14 million in regular operational costs. The company initially gained attention for its innovative yeast-based food ingredients, particularly a vegan protein product that garnered interest from numerous food and nutritional supplement firms globally. However, despite producing several tons of this product, NextFerm has repeatedly recorded financial losses and has been unable to achieve production scale without further investment.
Investors were initially attracted to the company due to two additional products designed to diversify risk and drive cash flow until the main product gained traction. Unfortunately, these ventures did not yield significant revenues, contributing to the company’s financial woes. For instance, a licensed yeast-based baking improvement product had its marketing rights revoked, and a food supplement sold in North America could not secure funds for clinical validation or effective marketing.
NextFerm’s revenue was inadequate, falling to just $174,000 last year, down from $283,000 in 2023. The company reported losses totaling $5.3 million last year alone, extending its total losses to $37 million since inception. To mitigate costs, NextFerm laid off most of its workforce in 2024, aiming to reduce annual expenses to $2 million while continuing a partnership in India for production and marketing.
The company indicated that its recent operational decisions stem from the inability to sell $900,000 worth of equipment, inhibiting further funding for operations. CEO Boaz Noy acknowledged the challenges facing the food-tech sector, stating the company is now concentrating on a limited scope of activity to seek profitability quickly. The current market conditions for food technologies and capital investments remain bleak, prompting the company to continue exploring possible solutions.
The content above is a summary. For more details, see the source article.